Point72 Asset Management
LXRX icon

Point72 Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Point72 Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8M Buy
8,251,325
+436,719
+6% +$851K 0.02% 896
2026
Q1 		$12.2M Buy
7,814,606
+7,530,581
+2,651% +$11M 0.02% 1111
2025
Q4 		$327K Buy
+284,025
New +$390K ﹤0.01% 3443
2025
Q1 		– Sell
-8,988,421
Closed -$6.64M – 2326
2024
Q4 		$6.64M Buy
8,988,421
+7,758,371
+631% +$9.35M 0.01% 856
2024
Q3 		$1.93M Sell
1,230,050
-2,891,141
-70% -$5.15M ﹤0.01% 1208
2024
Q2 		$6.92M Buy
4,121,191
+3,536,805
+605% +$6.34M 0.02% 745
2024
Q1 		$1.4M Buy
+584,386
New +$1.26M ﹤0.01% 1377
2023
Q2 		– Sell
-516,367
Closed -$1.25M – 2519
2023
Q1 		$1.25M Sell
516,367
-827,764
-62% -$1.9M ﹤0.01% 1066
2022
Q4 		$2.57M Sell
1,344,131
-2,269,369
-63% -$4.83M 0.01% 892
2022
Q3 		$8.67M Buy
+3,613,500
New +$10M 0.03% 546
2019
Q4 		– Sell
-528,100
Closed -$1.59M – 1120
2019
Q3 		$1.59M Buy
+528,100
New +$1.64M 0.01% 622
2017
Q2 		– Sell
-382,500
Closed -$5.49M – 933
2017
Q1 		$5.49M Buy
+382,500
New +$5.68M 0.03% 509

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Point72 Asset Management's LXRX Position: Q2 2026 in Review

Point72 Asset Management increased its Lexicon Pharmaceuticals (LXRX) stake by 5.6% in Q2 2026, buying an estimated $851K and bringing the position to 8,251,325 shares worth $19.8M. The position accounts for 0.02% of the portfolio, ranked #896.

Point72 Asset Management first reported a position in LXRX in Q1 2017 and has held it in 12 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Point72 Asset Management held 8,251,325 shares of Lexicon Pharmaceuticals worth $19.8M as of Q2 2026.
  • Point72 Asset Management bought 436,719 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $851K.
  • Lexicon Pharmaceuticals made up 0.02% of Point72 Asset Management's portfolio in Q2 2026, its #896 holding.
  • Point72 Asset Management first reported a position in Lexicon Pharmaceuticals in Q1 2017 and has held it in 12 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.